Form 8-K - Current report:
SEC Accession No. 0001576885-24-000032
Filing Date
2024-02-01
Accepted
2024-02-01 07:16:51
Documents
17
Period of Report
2024-02-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abos-20240201.htm   iXBRL 8-K 30140
2 EX-99.1 jimdannouncement13024.htm EX-99.1 6531
6 jimdannouncement13024001.jpg GRAPHIC 243828
7 jimdannouncement13024002.jpg GRAPHIC 171372
  Complete submission text file 0001576885-24-000032.txt   742643

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20240201.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20240201_lab.xml EX-101.LAB 24833
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20240201_pre.xml EX-101.PRE 13043
18 EXTRACTED XBRL INSTANCE DOCUMENT abos-20240201_htm.xml XML 2809
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 24585023
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)